Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO176 an AntiCD47 Antibody in patients with select solid tumors httpswww.businesswire.comnewshome20190206005055enArchOncologyAnnouncesPatientDosedPhase1Â
Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody in patients with select solid tumors https://www.businesswire.com/news/home/20190206005055/en/Arch-Oncology-Announces-Patient-Dosed-Phase-1 …
More From BioPortfolio on "Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody in patients with select solid tumors https://www.businesswire.com/news/home/20190206005055/en/Arch-Oncology-Announces-Patient-Dosed-Phase-1 …"